MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--Fluid monitoring with OptiVol® Fluid Status Monitoring is a more accurate predictor of worsening heart failure compared to daily weight monitoring in heart failure patients with implantable devices, according to results released today from the FAST (Fluid Accumulation Status Trial) clinical trial. Results showed that Medtronic, Inc. (NYSE: MDT) OptiVol® Fluid Status Monitoring, which measures changes in fluid build up in the chest cavity, predicted 76 percent of future heart failure events as compared to only 23 percent detected by weight monitoring alone. In other words, OptiVol was three times more sensitive. FAST findings were presented as a late breaking clinical trial during the 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Boston.
